The importance of patent oppositions in assisting patent examination
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the parallel session “Preventing bad patents: The role of patent examination.”
Civil Society and Patent Oppositions
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the plenary session “The role of civil society in the TRIPS flexibilities implementation.”
Argentina SOF Prodrug Decision
Amicus Brief Filed in Oil States vs. Greene Energy Group Supreme Court Case: The Critical Role of Patent Challenges in Increasing Competition and Reducing Drug Prices
In 2011, Congress passed the Leahy-Smith America Invents Act (“AIA”) to curb the spread of unmerited patents, stop abusive litigation, and ensure a fair playing field for patent applicants. Leahy-Smith America Invents Act, Pub. L. No. 112- 20, 125 Stat. 284, 35 U.S.C. § 1 et seq. (2011). In the face of industry overreliance on…
America’s Overspend: How the Pharmaceutical Patent Problem is Fueling High Drug Prices
The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs
Policy Brief: How the Supreme Court Patent Case Could Raise Drug Prices
With the majority of voters on both sides of the aisle saying Congress’s top priority should be lowering high drug costs, an upcoming U.S. Supreme Court case could significantly hamper the country’s ability to lower the price of medicine and assess and remove unmerited pharmaceutical patents. This policy brief examines the little-discussed health implications of…
FDA Submission for Administering The Hatch-Waxman Amendments: Ensuring A Balance Between Innovation And Access
“Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” was a meeting held on July 18, 2017 to provide the public an opportunity to submit comments concerning administration of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) to help ensure the intended balance between encouraging innovation in drug…
The Roadmap Special Edition Report on Dolutegravir
This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG.
The critical role of civil society in shaping the market for antiretroviral therapy and direct-acting antivirals
Civil society – in particular people living with and affected by HIV/AIDS – helped shape the market for antiretroviral drugs in low- and middle-income countries. There is a critical need to support civil society interventions that will similarly impact treatment access for hepatitis C.
The HIV Drug Pipeline and its Patents
The Roadmap is intended to help expand access to the next generation of life-saving ARVs in multiple ways. The pages that follow summarize clinical, cost, and legal/patent information around key pipeline drugs for HIV/AIDS.